Giving a talk about how China’s new patent law and recent developments impact biotech/pharma IP at the VESPA/VIPS Annual Autumn Seminar

2021年9月24日

Vice President Jennifer Che gave a talk at the Swiss Patent Attorney Associations and the Swiss Professional Attorney Association of Industrial Patent Attorneys (VESPA/VIPS) annual autumn seminar about key upcoming changes in China’s new Patent Law as well as other related new measures that are particularly relevant to pharma/biotech companies, including patent term extension, patent linkage, post-filing data, litigation reform, and patent eligibility in the biotech/pharma area.

我們過去活動

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

2025年11月26日

Jennifer Che has been Recognized as IAM Global Leaders 2026

2025年11月4日

Eagle IP is Coming to San Francisco and Washington DC!

2025年10月15日

Jennifer Che has been listed on the IAM Strategy 300

2025年8月15日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

2025年7月3日

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Recommended Insights

Why Do Examiners Fail to Recognize the Importance of my “Parameter Features”?

2025年5月28日

The Impact of Parameter Features on Inventiveness ”Parameter features” – numerical or mathematical expressions that define the quantity or physical properties of a subject – frequently appear as technical features within a claim. Often described as numerical ranges or measurements, they frequently play a critical role in addressing technical problems. However, in practice, Examiners and […]

New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference

2024年3月21日

Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]

Foreign companies transferring IP out of China: things to know

2018年10月25日

Inventions made in China Most foreign companies with R&D sites in China are aware of the fact that inventors having inventions made in China have to obtain permission before they can file patent applications outside of China for these Chinese inventions. It doesn’t matter if the owner of the business is a foreign entity. Patent […]

Compositions Limited by Use: A Cautionary Tale

2022年10月26日

Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]